The healthcare sector has long been a favorite for investors seeking stability and growth, and 2026 is no exception. With two major ETFs vying for attention—State Street's Health Care Select Sector SPDR Fund (XLV) and VanEck's Biotech ETF (BBH)—investors face a tough choice. A recent analysis by The Motley Fool pits these two funds against each other, offering valuable insights for anyone looking to add healthcare exposure to their portfolio. Let's break down the key differences and help you decide which ETF might be the better buy in 2026.

Understanding the Contenders: XLV vs. BBH

Before diving into performance, it's essential to understand what each ETF offers. XLV tracks the Health Care Select Sector Index, which includes a broad range of healthcare companies—from pharmaceuticals and biotech to medical devices and managed care. This diversification makes XLV a core holding for investors seeking broad exposure to the sector.

On the other hand, BBH focuses specifically on the biotechnology industry, as tracked by the MVIS US Listed Biotech 25 Index. This fund concentrates on a smaller set of biotech firms, often with higher growth potential but also higher volatility. BBH's top holdings include names like Amgen, Gilead Sciences, and Moderna, making it a more aggressive play.

Key Differences at a Glance

  • XLV: Broad diversification, lower volatility, includes pharma, biotech, and healthcare services.
  • BBH: Concentrated in biotech, higher growth potential, but with increased risk.

Performance and Risk: A Tale of Two ETFs

According to The Motley Fool's analysis, past performance reveals a clear divergence. Over recent years, BBH has outperformed XLV in bull markets, thanks to the explosive growth of biotech innovators. However, when the market turns bearish, BBH tends to fall harder, while XLV shows more resilience due to its diversified nature.

For example, in the 2020-2021 biotech boom, BBH soared, but it also suffered significant drawdowns in 2022 when the sector corrected. XLV, by contrast, provided steadier returns, albeit with lower upside. The Motley Fool notes that investors with a higher risk tolerance might prefer BBH for its growth potential, while conservative investors may lean toward XLV for stability.

Volatility and Drawdowns

BBH's beta is higher than XLV's, meaning it moves more with the market. In the event of a market downturn, BBH could see steeper declines. XLV, being more diversified, offers a smoother ride. For those nearing retirement or seeking income, XLV's dividend yield is generally higher, though BBH has also paid dividends.

Fundamentals and Valuation

When comparing fundamentals, the analysis highlights that BBH's holdings often trade at higher price-to-earnings (P/E) ratios due to expected future growth. XLV's portfolio, on average, has lower valuations, reflecting its more mature business mix. This difference can be crucial: if you believe biotech innovation will drive earnings, BBH's premium may be justified.

However, The Motley Fool warns that high valuations can lead to sharp corrections if earnings disappoint. XLV's steadier earnings profile provides a margin of safety. Additionally, BBH's concentration in a handful of large-cap biotechs means its performance is heavily influenced by a few key names, such as Amgen or Vertex Pharmaceuticals.

Top Holdings Comparison

XLV's top holdings include UnitedHealth Group, Johnson & Johnson, and Pfizer—companies with massive scale and diversified revenue streams. BBH's top holdings are more research-driven, with firms like Biogen and Regeneron. This difference in business models impacts revenue stability and growth trajectories.

Which ETF Fits Your Portfolio?

Ultimately, the right choice depends on your investment goals and risk appetite. If you're looking for a core healthcare holding that can weather market storms, XLV is a solid choice. It offers broad exposure and lower volatility, making it suitable for long-term investors.

But if you're willing to accept higher volatility for the chance at outsized gains, BBH might be more appealing. This ETF is best for those with a longer time horizon and a stomach for drawdowns. The Motley Fool suggests that a combination of both could be a balanced approach, allowing you to capture growth while maintaining some stability.

Consider Your Time Horizon

Short-term traders may find BBH's price swings attractive, but long-term investors should weigh the impact of volatility on their portfolio. XLV's steadiness can help with compounding, while BBH's peaks and troughs might test your discipline.

Conclusion: Making the Call

In the battle of healthcare ETFs, there is no one-size-fits-all answer. XLV offers reliability and diversification, making it a cornerstone for many portfolios. BBH, meanwhile, is a high-octane option for those betting on biotech breakthroughs. As The Motley Fool's analysis suggests, your choice should align with your financial goals, risk tolerance, and investment horizon.

Key Takeaways

  • XLV is the safer, more diversified pick for broad healthcare exposure.
  • BBH delivers higher growth potential but with greater volatility.
  • Consider blending both ETFs to balance risk and reward.
  • Always assess your own risk tolerance and investment timeline before choosing.

Whichever you choose, staying invested in healthcare can be a smart move, given the sector's long-term demographic tailwinds. For personalized advice, consult a financial advisor to tailor these options to your specific situation.